Stock 002399 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Equities

002399

CNE100000P02

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
9.19 CNY +2.68% Intraday chart for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. +1.43% -21.65%
Apr. 02 Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane MT
Apr. 02 Thailand Food and Drug Administration Approves for Sales in the Market of Exarane Produced by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s Wholly-Owned Subsidiary Shenzhen Techdow Medicine Co., Ltd CI

Business Summary

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The Company distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Number of employees: 2,080

Sales per Business

CNY in Million2022Weight2023Weight Delta
Preparation
54.7 %
3,210 44.8 % 2,979 54.7 % -7.21%
API
24.0 %
2,674 37.3 % 1,308 24.0 % -51.09%
Contract Development and Manufacturing Operations
17.8 %
1,084 15.1 % 967 17.8 % -10.80%
Others
3.5 %
191 2.7 % 192 3.5 % +0.35%

Sales per region

CNY in Million2022Weight2023Weight Delta
Europe
48.0 %
3,730 52.1 % 2,616 48.0 % -29.87%
United States
23.5 %
1,387 19.4 % 1,278 23.5 % -7.90%
Other Countries
20.6 %
1,290 18.0 % 1,122 20.6 % -13.01%
China
7.6 %
643 9.0 % 412 7.6 % -35.83%
Hong Kong
0.3 %
103 1.4 % 18 0.3 % -82.43%

Managers

Managers TitleAgeSince
Yu Shan FOU
 Founder 64 98-04-20
Tan Li FOU
 Founder 60 98-04-20
Juan Chen DFI
 Director of Finance/CFO 49 23-08-20
Ming Jie Wu CTO
 Chief Tech/Sci/R&D Officer - -
Ji Lan Su BRD
 Director/Board Member 45 04-01-31
Wen Xuan Zhang IRC
 Investor Relations Contact 35 -
Tao Han PRN
 Corporate Officer/Principal - -
Feng Qi Qian SEC
 Corporate Secretary 39 21-07-31

Members of the board

Members of the board TitleAgeSince
Tan Li FOU
 Founder 60 98-04-20
Peng Huang BRD
 Director/Board Member 75 23-05-21
Li Li FOU
 Founder 60 98-04-20
Yu Shan FOU
 Founder 64 98-04-20
Hai Jun Tang BRD
 Director/Board Member 46 01-01-31
Ji Lan Su BRD
 Director/Board Member 45 04-01-31
Ze Hui Zheng CHM
 Chairman 54 14-05-15
Chu An Lü BRD
 Director/Board Member 54 19-12-17
Ming Yi BRD
 Director/Board Member 47 23-05-21
Ping Zhang BRD
 Director/Board Member 59 23-05-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 220,094,500 0 0 17.01 %
Stock B 1 1,247,201,704 249,584,561 ( 20.01 %) 0

Shareholders

NameEquities%Valuation
AVIC Trust Co., Ltd.
5.738 %
12,629,500 5.738 % 4 M ¥
OrbiMed Advisors Private Equity
4.832 %
10,634,500 4.832 % 4 M ¥
Dimensional Fund Advisors Ltd.
0.0769 %
169,283 0.0769 % 60 131 ¥
Truvalue Asset Management Co. Ltd.
0.0632 %
139,000 0.0632 % 49 374 ¥
State Street Global Advisors Ltd.
0.0511 %
112,567 0.0511 % 39 985 ¥
DFA Australia Ltd.
0.000757 %
1,666 0.000757 % 592 ¥
NameEquities%Valuation
Li Li
41.24 %
514,349,899 41.24 % 594 M ¥
Tan Li
32.72 %
408,041,280 32.72 % 471 M ¥
Yu Shan
3.722 %
46,425,600 3.722 % 54 M ¥
Shenzhen Hepalink Pharmaceutical Group Co. Ltd. ESOP
1.212 %
15,118,035 1.212 % 17 M ¥
Yinhua Fund Management Co., Ltd.
0.2330 %
2,906,354 0.2330 % 3 M ¥
China Southern Asset Management Co., Ltd.
0.2285 %
2,850,080 0.2285 % 3 M ¥
GF Fund Management Co., Ltd.
0.1720 %
2,145,091 0.1720 % 2 M ¥
Tian Hong Asset Management Co., Ltd.
0.1128 %
1,406,534 0.1128 % 2 M ¥
Fullgoal Fund Management Co., Ltd.
0.0629 %
784,500 0.0629 % 906 349 ¥
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)
0.0415 %
517,420 0.0415 % 597 786 ¥

Holdings

NameEquities%Valuation
RESVERLOGIX CORP.
31.34%
 85,286,524 31.34% 3,582,034 $
QUEST PHARMATECH INC.
14.78%
 25,000,000 14.78% 525,000 $
GT BIOPHARMA, INC.
6.65%
 91,860 6.65% 406,940 $

Company contact information

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

21 Langshan Road Song Ping Shan

518057, Shenzhen

+

http://www.hepalink.com
address Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(002399)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Generic Pharmaceuticals

Sales per Business

Sales per region

Ratings for Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
9.19 CNY
Average target price
6.4 CNY
Spread / Average Target
-30.36%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. Stock Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
-21.65% 1.67B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.89B
SANDOZ GROUP AG Stock Sandoz Group AG
+13.49% 14.45B
CIPLA LIMITED Stock Cipla Limited
+13.52% 13.63B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+38.39% 11.49B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.85B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+6.35% 5.06B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Stock Shenzhen Salubris Pharmaceuticals Co., Ltd.
-5.36% 4.66B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002399 Stock
  4. Company Shenzhen Hepalink Pharmaceutical Group Co., Ltd.